"Tyrosine 3-Monooxygenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of L-tyrosine, tetrahydrobiopterin, and oxygen to 3,4-dihydroxy-L-phenylalanine, dihydrobiopterin, and water. EC 1.14.16.2.
| Descriptor ID |
D014446
|
| MeSH Number(s) |
D08.811.682.690.708.923 D12.776.556.579.374.925
|
| Concept/Terms |
Tyrosine 3-Monooxygenase- Tyrosine 3-Monooxygenase
- 3-Monooxygenase, Tyrosine
- Tyrosine 3 Monooxygenase
- Tyrosine Hydroxylase
- Hydroxylase, Tyrosine
|
Below are MeSH descriptors whose meaning is more general than "Tyrosine 3-Monooxygenase".
Below are MeSH descriptors whose meaning is more specific than "Tyrosine 3-Monooxygenase".
This graph shows the total number of publications written about "Tyrosine 3-Monooxygenase" by people in this website by year, and whether "Tyrosine 3-Monooxygenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 1 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 3 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 3 | 3 |
| 2006 | 1 | 4 | 5 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 4 | 4 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 3 | 3 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tyrosine 3-Monooxygenase" by people in Profiles.
-
Nigral-specific increase in ser31 phosphorylation compensates for tyrosine hydroxylase protein and nigrostriatal neuron loss: Implications for delaying parkinsonian signs. Exp Neurol. 2023 10; 368:114509.
-
Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
-
Experimental colitis promotes sustained, sex-dependent, T-cell-associated neuroinflammation and parkinsonian neuropathology. Acta Neuropathol Commun. 2021 08 19; 9(1):139.
-
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
-
Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019 11 01; 142(11):3565-3579.
-
Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease. J Neuroimmune Pharmacol. 2019 06; 14(2):173-187.
-
Self-administration of methamphetamine alters gut biomarkers of toxicity. Eur J Neurosci. 2017 Aug; 46(3):1918-1932.
-
Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
-
Parkinsonian monkeys with prior levodopa-induced dyskinesias followed by fetal dopamine precursor grafts do not display graft-induced dyskinesias. J Comp Neurol. 2017 02 15; 525(3):498-512.
-
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies. Neurobiol Dis. 2015 Jun; 78:162-71.